Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pls... Nothing has changed at all here... Positive news as it seems is pretty well a guarentee, huuuuuge gains here for anyone smart enough to hold and buy the foolish folks shares. Anyone who spends time to sit here negatively posting away has been quietly buying all the shares they can. And guess what... They love this scare... They're all out in full force.
Sure seems like a scare tactic to me... Not selling a single share and I will be standing by ready to buy more.
HOLY SHhhhhhhhhhhhhhhoot!!!! NICE FIND!!!! BMSN
Yea this is a very important find... Just adds to the huge pile of dd.
That will give everyone the kick start they're looking for. Excellent work
Can someone explain to me the benefit of investing in both bmsn and entb. Doesn't bmsn have greater potential? Not trying to be rude... I just have more powder and hoping for some clarity before the market opens. Don't get me wrong entb is going to fly once news hits for bmsn.
Here's a question... I've read posts about the percentage of applicants that get ind approval, it would be interesting to know the percentage that are approved after a second round of questions has be issued. Over 90%?
I was referring to her post about the conversation with dr ichim
Picked up some 30s :)
Still trying to scare people with these bogus cases? Your posts are getting very stale.
Have you read the dd he has posted on this site... If not go read the sticky. He has contributed so much excellent dd he can post what ever he wants... His credibility here is very high.
Yea I don't know where all these chart experts came from but seems like they might be out of there element here... They know what there talking about but it doesn't necessarily apply in this sub penny situation ... When news hits this is gunna take off like crazy.
Ya but the chances of this not being approved are extremely slim considering its a better candidate than comparable products that have received orphan drug status... If they have another round of questions and it dips just buy more...we're going to see this approved, IMHO
Who in the right mind would want to bail on this.
This stock has been beyond manipulated... There has been no reason for it to drop other than dilution which is currently over. Considering the potential here, unbelievable value at this level.
Oh man I'd be happy if I could pick up some .0024 again before this does a blast off
What are you upset about? You should be happy the mms are keeping this down... Gives you a chance to pick up more before approval happens.
And also remember if it does dip down.... Buy more shares!!!!!
.002s are gone... Too close to news now. There's no stopping this train
Huge money coming up
Very nice!
They have 30 days man it's on the FDA web site... Can't be any more clear...
They are well ahead of the schedule they posted in there pr
They are on a 30 day timer now... We will find out any time in 30 days and if we don't hear by then.... We are ok to start trials. This is the best risk vs reward stock I have ever seen at these prices. If you go to the FDA web site it's clearly stated.
Any time from now to September
Agreed I will also be picking up pre weekend shares! Too cheap and too close to pass up!
Meach really went above and beyond to straighten out any doubts about BMSN... Believe me everything is 100 % legit here and is fully moving forward as expected.
These are actual facts from contact with FDA and BMSN that Meach acquired. (Make sure to scroll to bottom)
Time To Get Rich: Meach DD
I have been in contact with some choice individuals who know the bio sector well.
1)IND #13898 (with company MEDS, this has the same number of digits as IND#15376.
OH WAIT, THE SAME AS A PRE-EXISTING DRUG?
100% legitimate- the drug is subject to FDA laws governing confidentiality- these laws do not apply unless it is not recognized by the FDA, nor a part of it.
Aka, The claim about the digits being wrong is wrong.
2) BMSN and HemaXellerate could NOT have failed trials yet. THEY ARE NOT YET IN TRIALS.
Those who said BMSN is going bankrupt and that HemaXellerate was a flop are WRONG. You cannot fail trials previous to starting them. :)
3) The FDA treats ALLLLLLLLL New IND applications before starting CLINICAL TRIALS AS CONFIDENTIAL. This is simply due to insider trading. The laws applicable to confidentiality are
Quote:
§ 601.50 Confidentiality of data and information in an investigational new drug notice for a biological product.
(a) The existence of an IND notice for a biological product will not be disclosed by the Food and Drug Administration unless it has previously been publicly disclosed or acknowledged.
(b) The availability for public disclosure of all data and information in an IND file for a biological product shall be handled in accordance with the provisions established in §601.51.
(c) Notwithstanding the provisions of §601.51, the Food and Drug Administration shall disclose upon request to an individual on whom an investigational biological product has been used a copy of any adverse reaction report relating to such use.
[39 FR 44656, Dec. 24, 1974]
AND
§ 601.51
Confidentiality of data and information in applications for biologics licenses.
(a) For purposes of this section the biological product file includes all data and information submitted with or incorporated by reference in any application for a biologics license, IND's incorporated into any such application, master files, and other related submissions. The availability for public disclosure of any record in the biological product file shall be handled in accordance with the provisions of this section.
(b) The existence of a biological product file will not be disclosed by the Food and Drug Administration before a biologics license application has been approved unless it has previously been publicly disclosed or acknowledged. The Food and Drug Administration will maintain a list available for public disclosure of biological products for which a license application has been approved.
(c) If the existence of a biological product file has not been publicly disclosed or acknowledged, no data or information in the biological product file is available for public disclosure.
(d) (1) If the existence of a biological product file has been publicly disclosed or acknowledged before a license has been issued, no data or information contained in the file is available for public disclosure before such license is issued, but the Commissioner may, in his discretion, disclose a summary of such selected portions of the safety and effectiveness data as are appropriate for public consideration of a specific pending issue, e.g., at an open session of a Food and Drug Administration advisory committee or pursuant to an exchange of important regulatory information with a foreign government.
(2) Notwithstanding paragraph (d)(1) of this section, FDA will make available to the public upon request the information in the IND that was required to be filed in Docket Number 95S-0158 in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, for investigations involving an exception from informed consent under § 50.24 of this chapter. Persons wishing to request this information shall submit a request under the Freedom of Information Act.
(e) After a license has been issued, the following data and information in the biological product file are immediately available for public disclosure unless extraordinary circumstances are shown:
(1) All safety and effectiveness data and information.
(2) A protocol for a test or study, unless it is shown to fall within the exemption established for trade secrets and confidential commercial or financial information in § 20.61 of this chapter.
(3) Adverse reaction reports, product experience reports, consumer complaints, and other similar data and information, after deletion of:
(i) Names and any information that would identify the person using the product.
(ii) Names and any information that would identify any third party involved with the report, such as a physician or hospital or other institution.
(4) A list of all active ingredients and any inactive ingredients previously disclosed to the public, as defined in § 20.81 of this chapter.
(5) An assay method or other analytical method, unless it serves no regulatory or compliance purpose and it is shown to fall within the exemption established in § 20.61 of this chapter.
(6) All correspondence and written summaries of oral discussions relating to the biological product file, in accordance with the provisions of part 20 of this chapter .
(7) All records showing the manufacturer's testing of a particular lot, after deletion of data or information that would show the volume of the drug produced, manufacturing procedures and controls, yield from raw materials, costs, or other material falling within § 20.61 of this chapter.
( All records showing the testing of and action on a particular lot by the Food and Drug Administration.
(f) The following data and information in a biological product file are not available for public disclosure unless they have been previously disclosed to the public as defined in § 20.81 of this chapter or they relate to a product or ingredient that has been abandoned and they no longer represent a trade secret or confidential commercial or financial information as defined in § 20.61 of this chapter :
(1) Manufacturing methods or processes, including quality control procedures.
(2) Production, sales, distribution, and similar data and information, except that any compilation of such data and information aggregated and prepared in a way that does not reveal data or information which is not available for public disclosure under this provision is available for public disclosure.
(3) Quantitative or semiquantitative formulas.
(g) For purposes of this regulation, safety and effectiveness data include all studies and tests of a biological product on animals and humans and all studies and tests on the drug for identity, stability, purity, potency, and bioavailability.
By the way, this explains WHY it cannot be found on the FDA site.
4) look at every other company with a similar structure.
All diluted to pay for trials.... According to companies in Phase 1 clinical trials with drugs dealing with stem cells and bone marrow- we are looking at 11.7c/share END OF PHASE 1.
5) NO OTHER SIMILAR COMPANIES TO BMSN EVER DID A R/S UPON PHASE 1 CLINICAL TRIALS UNLESS THEY ARE SHAMS. BMSN IS NOT A SCAM- I HAVE VERIFIED THIS BY FDA, And various other individuals I will not disclose.
6)BMSN has gotten everything done for this drug INCREDIBLY quickly, I can understand the desire to deny its credibility. When things are done exceptionally, it often causes people to doubt legitimacy.
7) Finally, yes, the FDA has verified. HemaXellerate is legitimate.
LOOK AT 7 AGAIN
9) Re-read 7.
10)Please read 7 again
11)As always, IMHO.
12) Thank you. My investigation is done til' the next thing. Time to get rich.
13) By the way, its no secret that about ONE MONTH AGO they diluted shares, but that is a MONTH AGO. it was posted in their filings. Do you not read up on the company you are invested in?....Sheesh, people treat the stock market like gambling....
Use your brain, do your DD, learn, educate yourself and grow.
IMHO :)
People need to read this post from meach...it really exposes the truth as it comes from the most reliable source available. There is absolutely no reason to believe BMSN is doing anything but an outstanding job with this company.
Time To Get Rich: Meach DD
I have been in contact with some choice individuals who know the bio sector well.
1)IND #13898 (with company MEDS, this has the same number of digits as IND#15376.
OH WAIT, THE SAME AS A PRE-EXISTING DRUG?
100% legitimate- the drug is subject to FDA laws governing confidentiality- these laws do not apply unless it is not recognized by the FDA, nor a part of it.
Aka, The claim about the digits being wrong is wrong.
2) BMSN and HemaXellerate could NOT have failed trials yet. THEY ARE NOT YET IN TRIALS.
Those who said BMSN is going bankrupt and that HemaXellerate was a flop are WRONG. You cannot fail trials previous to starting them. :)
3) The FDA treats ALLLLLLLLL New IND applications before starting CLINICAL TRIALS AS CONFIDENTIAL. This is simply due to insider trading. The laws applicable to confidentiality are
Quote:
§ 601.50 Confidentiality of data and information in an investigational new drug notice for a biological product.
(a) The existence of an IND notice for a biological product will not be disclosed by the Food and Drug Administration unless it has previously been publicly disclosed or acknowledged.
(b) The availability for public disclosure of all data and information in an IND file for a biological product shall be handled in accordance with the provisions established in §601.51.
(c) Notwithstanding the provisions of §601.51, the Food and Drug Administration shall disclose upon request to an individual on whom an investigational biological product has been used a copy of any adverse reaction report relating to such use.
[39 FR 44656, Dec. 24, 1974]
AND
§ 601.51
Confidentiality of data and information in applications for biologics licenses.
(a) For purposes of this section the biological product file includes all data and information submitted with or incorporated by reference in any application for a biologics license, IND's incorporated into any such application, master files, and other related submissions. The availability for public disclosure of any record in the biological product file shall be handled in accordance with the provisions of this section.
(b) The existence of a biological product file will not be disclosed by the Food and Drug Administration before a biologics license application has been approved unless it has previously been publicly disclosed or acknowledged. The Food and Drug Administration will maintain a list available for public disclosure of biological products for which a license application has been approved.
(c) If the existence of a biological product file has not been publicly disclosed or acknowledged, no data or information in the biological product file is available for public disclosure.
(d) (1) If the existence of a biological product file has been publicly disclosed or acknowledged before a license has been issued, no data or information contained in the file is available for public disclosure before such license is issued, but the Commissioner may, in his discretion, disclose a summary of such selected portions of the safety and effectiveness data as are appropriate for public consideration of a specific pending issue, e.g., at an open session of a Food and Drug Administration advisory committee or pursuant to an exchange of important regulatory information with a foreign government.
(2) Notwithstanding paragraph (d)(1) of this section, FDA will make available to the public upon request the information in the IND that was required to be filed in Docket Number 95S-0158 in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, for investigations involving an exception from informed consent under § 50.24 of this chapter. Persons wishing to request this information shall submit a request under the Freedom of Information Act.
(e) After a license has been issued, the following data and information in the biological product file are immediately available for public disclosure unless extraordinary circumstances are shown:
(1) All safety and effectiveness data and information.
(2) A protocol for a test or study, unless it is shown to fall within the exemption established for trade secrets and confidential commercial or financial information in § 20.61 of this chapter.
(3) Adverse reaction reports, product experience reports, consumer complaints, and other similar data and information, after deletion of:
(i) Names and any information that would identify the person using the product.
(ii) Names and any information that would identify any third party involved with the report, such as a physician or hospital or other institution.
(4) A list of all active ingredients and any inactive ingredients previously disclosed to the public, as defined in § 20.81 of this chapter.
(5) An assay method or other analytical method, unless it serves no regulatory or compliance purpose and it is shown to fall within the exemption established in § 20.61 of this chapter.
(6) All correspondence and written summaries of oral discussions relating to the biological product file, in accordance with the provisions of part 20 of this chapter .
(7) All records showing the manufacturer's testing of a particular lot, after deletion of data or information that would show the volume of the drug produced, manufacturing procedures and controls, yield from raw materials, costs, or other material falling within § 20.61 of this chapter.
( All records showing the testing of and action on a particular lot by the Food and Drug Administration.
(f) The following data and information in a biological product file are not available for public disclosure unless they have been previously disclosed to the public as defined in § 20.81 of this chapter or they relate to a product or ingredient that has been abandoned and they no longer represent a trade secret or confidential commercial or financial information as defined in § 20.61 of this chapter :
(1) Manufacturing methods or processes, including quality control procedures.
(2) Production, sales, distribution, and similar data and information, except that any compilation of such data and information aggregated and prepared in a way that does not reveal data or information which is not available for public disclosure under this provision is available for public disclosure.
(3) Quantitative or semiquantitative formulas.
(g) For purposes of this regulation, safety and effectiveness data include all studies and tests of a biological product on animals and humans and all studies and tests on the drug for identity, stability, purity, potency, and bioavailability.
By the way, this explains WHY it cannot be found on the FDA site.
4) look at every other company with a similar structure.
All diluted to pay for trials.... According to companies in Phase 1 clinical trials with drugs dealing with stem cells and bone marrow- we are looking at 11.7c/share END OF PHASE 1.
5) NO OTHER SIMILAR COMPANIES TO BMSN EVER DID A R/S UPON PHASE 1 CLINICAL TRIALS UNLESS THEY ARE SHAMS. BMSN IS NOT A SCAM- I HAVE VERIFIED THIS BY FDA, And various other individuals I will not disclose.
6)BMSN has gotten everything done for this drug INCREDIBLY quickly, I can understand the desire to deny its credibility. When things are done exceptionally, it often causes people to doubt legitimacy.
7) Finally, yes, the FDA has verified. HemaXellerate is legitimate.
LOOK AT 7 AGAIN
9) Re-read 7.
10)Please read 7 again
11)As always, IMHO.
12) Thank you. My investigation is done til' the next thing. Time to get rich.
13) By the way, its no secret that about ONE MONTH AGO they diluted shares, but that is a MONTH AGO. it was posted in their filings. Do you not read up on the company you are invested in?....Sheesh, people treat the stock market like gambling....
Use your brain, do your DD, learn, educate yourself and grow.
IMHO :)